Wentao Wu
Operationeel Directeur bij Xynomic Pharmaceuticals, Inc.
Actieve functies van Wentao Wu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Xynomic Pharmaceuticals, Inc.
 Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Operationeel Directeur | - | - |
Loopbaan van Wentao Wu
Eerdere bekende functies van Wentao Wu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| AMERICAN ORIENTAL BIOENGINEERING, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2004 | 01-01-2009 |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01-01-2002 | 01-01-2004 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Operationeel Directeur | 01-01-2019 | - |
Opleiding van Wentao Wu
| Purdue University | Doctorate Degree |
| Indiana University | Masters Business Admin |
Statistieken
Internationaal
| China | 4 |
| Verenigde Staten | 4 |
Operationeel
| Chief Operating Officer | 2 |
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AMERICAN ORIENTAL BIOENGINEERING, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Health Technology |
